ValuEngine Lowers Viking Therapeutics (VKTX) to Sell

ValuEngine cut shares of Viking Therapeutics (NASDAQ:VKTX) from a hold rating to a sell rating in a report released on Friday.

A number of other analysts also recently weighed in on VKTX. Maxim Group set a $5.00 price target on Viking Therapeutics and gave the stock a buy rating in a report on Thursday, August 10th. HC Wainwright reiterated a buy rating and set a $7.00 price target on shares of Viking Therapeutics in a report on Friday, November 10th. Finally, Roth Capital started coverage on Viking Therapeutics in a report on Tuesday, November 21st. They set a buy rating and a $5.00 price target for the company.

Shares of Viking Therapeutics (NASDAQ VKTX) opened at $3.02 on Friday. Viking Therapeutics has a 1-year low of $0.88 and a 1-year high of $3.24.

Viking Therapeutics (NASDAQ:VKTX) last issued its quarterly earnings results on Wednesday, November 8th. The biotechnology company reported ($0.22) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.19) by ($0.03). equities research analysts predict that Viking Therapeutics will post -0.86 EPS for the current year.

A number of institutional investors have recently modified their holdings of the business. Citadel Advisors LLC acquired a new stake in Viking Therapeutics during the 3rd quarter worth about $108,000. Renaissance Technologies LLC grew its holdings in Viking Therapeutics by 62.9% during the 1st quarter. Renaissance Technologies LLC now owns 265,800 shares of the biotechnology company’s stock worth $388,000 after acquiring an additional 102,600 shares during the period. Virtu KCG Holdings LLC acquired a new stake in Viking Therapeutics during the 2nd quarter worth about $124,000. Sphera Funds Management LTD. acquired a new stake in Viking Therapeutics during the 3rd quarter worth about $554,000. Finally, Sabby Management LLC acquired a new stake in Viking Therapeutics during the 2nd quarter worth about $525,000. Hedge funds and other institutional investors own 7.50% of the company’s stock.

TRADEMARK VIOLATION WARNING: “ValuEngine Lowers Viking Therapeutics (VKTX) to Sell” was originally posted by Week Herald and is the sole property of of Week Herald. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of US & international trademark & copyright law. The correct version of this report can be accessed at https://weekherald.com/2017/12/04/valuengine-lowers-viking-therapeutics-vktx-to-sell.html.

About Viking Therapeutics

Viking Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapies for metabolic and endocrine disorders. The Company’s clinical program, VK5211, is an orally available drug candidate, which is in Phase II clinical trial for acute rehabilitation following non-elective hip fracture surgery.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Viking Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply